Summary: Genmab A/S increases its share capital by 13,611 shares as a result of
employee warrant exercise.
Copenhagen, Denmark; November 21, 2007 - Genmab A/S (OMX: GEN) has decided to
increase its share capital by 13,611 shares as a consequence of the exercise of
employee warrants.
The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following prices per share of nominally DKK 1: 1,000 shares at DKK 37.00, 1,200
shares at DKK 86.00, 2,850 shares at DKK 89.50, 3,687 shares at DKK 101.00,
1,125 shares at DKK 114.00, 1,000 shares at DKK 173.00 and 2,749 shares at DKK
224.00. Proceeds to the company are approx. DKK 1.7 million (approx. TUSD 335).
The increase corresponds to approx. 0.03 % of the company's share capital.
The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company as of subscription, i.e.
inter alia full rights to dividends for the financial year 2007. The new shares
will be listed on the OMX Nordic Exchange Copenhagen A/S after registration with
the Danish Commerce and Companies Agency. Genmab A/S' current share capital
amounts to DKK 44,506,216 and will after the capital increase be DKK 44,519,827.
The capital increase is expected to be finalized shortly.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using unique,
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.
As Genmab advances towards a commercial future, we remain committed to our
primary goal of improving the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 55/2007
###
